Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NOV 002

Known as: NOV-002, NOV002, Oxidized Glutathione NOV-002 
A stabilized formulation of disodium glutathione disulfide (GSSG; oxidized glutathione) and cisplatin (1000:1) with potential chemoprotective and… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

CisplatinDrug CombinationsGlutathione Disulfide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
NOV-002, A Glutathione Disulfide Mimetic, Suppresses Tumor Cell Invasion and Metastasis
Metastasis is the major cause of death in cancer. Most therapies currently in the clinic aim to eradicate primary tumor, but do… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress.
The oxidized glutathione mimetic NOV-002 is a unique anti-tumor agent that not only has the ability to inhibit tumor cell… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer
NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell proliferation and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Preclinical pharmacokinetic analysis of NOV-002, a glutathione disulfide mimetic.
NOV-002 is a glutathione disulfide (GSSG) mimetic that is the subject of clinical investigation in oncology indications. GSSG is… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2010
2010
Protective effects of a glutathione disulfide mimetic (NOV-002) against cisplatin induced kidney toxicity.
NOV-002 is a glutathione disulfide (GSSG) mimetic with chemoprotective activity. Previous and ongoing clinical studies… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2010
2010
A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung…
LBA7007 Background: NOV-002 is a formulation of disodium glutathione disulfide (GSSG). GSSG is a naturally occurring substance… Expand
Is this relevant?
2008
2008
NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance.
NOV-002 is a novel glutathione disulfide mimetic that when administered in combination with standard chemotherapeutic regimens… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2008
2008
Pharmacology of a mimetic of glutathione disulfide, NOV-002.
NOV-002 is a novel therapeutic agent in development for oncology indications used in combination with chemotherapy. Clinical… Expand
Is this relevant?
2006
2006
NOV-002, a chemoprotectant/immunomodulator, added to first-line carboplatin/paclitaxel in advanced non-small cell lung cancer (NSCLC): A randomized Phase 1/2, open-label, controlled study.
17021 Background: NOV-002 is a proprietary formulation of oxidized glutathione that modulates production of cytokines and… Expand
Is this relevant?
Review
2005
Review
2005
Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets.
Anticancer drug development using the platform of glutathione (GSH), glutathione S-transferases (GST) and pathways that maintain… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE